课题基金 / 基金详情

Recruiting multiethnic populations to preclinical Alzheimers disease trials-Diversity Supplement

Recruiting multiethnic populations to preclinical Alzheimers disease trials-Diversity Supplement
招募多种族人群参加临床前阿尔茨海默病试验-多样性补充
批准号:
10791432
负责人:
Joshua Grill
金额:
$9.34万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-15 至 2025-04-30

项目摘要

项目成果

Joshua Grill的其他基金

相关文献

中文摘要
翻译
母研究项目摘要 阿尔茨海默病(AD)和相关痴呆症(ADRD)不成比例地影响代表性不足的种族和 民族社区。预计未来几年阿尔茨海默氏症患者的数量将增加, 这增加了公共卫生系统的负担。为了缓解这种情况,重要的是找到治疗方法 通过临床试验,可以减缓疾病的进展,特别是在不同的人群中。临床前AD试验 缺乏多样性,试验要求了解一个人的生物标志物状态,需要一个研究伙伴来登记 可以发挥作用。我们的项目重点是了解这些临床前试验要求的影响, 生物标志物披露和研究伴侣要求,在种族和民族群体之间存在差异。我们将使用 认知访谈,以检验我们的假设,即种族和民族群体在学习意愿上存在差异 生物标志物状态。我们还将使用以前开发的评估工具1,以评估对 不同群体之间的学习伙伴要求。我们认为,研究伙伴的要求不同, 影响种族和族裔群体之间参与的能力/意愿。这项工作将帮助我们收集数据, 指导临床前AD试验在代表性不足的人群中的招募,更好地了解对 在研究过程中的生物标志物披露,并了解对研究态度的差异 合作伙伴的要求,使调查人员可以调整,以帮助代表性不足的群体填补这一作用。
英文摘要
Abstract of Parent Research Project Alzheimer’s disease (AD) and related dementias (ADRD) disproportionately affect underrepresented racial and ethnic communities. The number of people with Alzheimer’s is expected to increase in the coming years, and with this an increased burden to the public health system. To alleviate this, it is important to find treatments through clinical trials that can slow disease progression, especially in diverse populations. Preclinical AD trials lack diversity, and the trial requirements of learning one’s biomarker status and needing a study partner to enroll could play a role. Our project focuses on understanding how the impact of these preclinical trial requirements, biomarker disclosure and study partner requirement, differs among racial and ethnic groups. We will use cognitive interviews to test our hypothesis that racial and ethnic groups differ in their willingness to learn biomarker status. We will also use a previously developed assessment instrument1, to assess attitudes toward the study partner requirement among diverse groups. We believe that the study partner requirement differentially affects ability/willingness to participate among racial and ethnic groups. This work will help us collect data to guide recruitment in preclinical AD trials in underrepresented groups, better understand attitudes toward biomarker disclosure during the research process and understand the differences in attitudes toward the study partner requirement so investigators can adjust to help underrepresented groups fill this role.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Patient and Family Member Reactions to Biomarker-Informed ADRD Diagnoses
Collaborative Approach for Asian Americans, Native Hawaiians, and Pacific Islanders Research and Education (CARE) 2.0
Summer Medical student Aging and Alzheimer disease Research Training (SMAART) program
  • 批准号:
    10617758
  • 项目类别:
  • 资助金额:
    $6.85万
  • 财政年份:
    2022
  • 负责人:
    Joshua Grill
  • 依托单位:
NIA/AA for Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (NIA/AA IMPACT-AD Course)